Bexicaserin

DB18885InvestigationalSmall molecule

Bexicaserin is under investigation in clinical trial NCT05626634 (Open-label, Long-term Safety Study of LP352 in Subjects With Developmental and Epileptic Encephalopathy).

Mechanism: Pharmacologically active on 5-hydroxytryptamine receptor 2C
Curator reviewed
Formula / weight: C₁₅H₁₉F₂N₃O · 295.334 g/mol (avg)
Also known as: (7R)-N-(2,2-difluoroethyl)-7-methyl-1,2,3,4,6,7-hexahydro[1,4]diazepino[6,7,1-hi]indole-8-carboxamide
Code names: LP352

Resolves to

Compound

UNIIR8XR1D6SCBCAS2035818-24-5

Structure

InChIKeyKGOOOHQKLRUVSF-VIFPVBQESA-NSMILESC[C@H]1CN2CCNCC3=CC=C(C(=O)NCC(F)F)C1=C23

Targets

P28335HTR2C

What you can answer from here — as of July 09, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

6Clinical trialsPhase, status and sponsor resolved per trial

5+ReferencesStructured and connected to the statements they support

Which drugs share a target with Bexicaserin, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account